Figure 2From: An effective and well-tolerated strategy in recurrent and/or metastatic head and neck cancer: successive lines of active chemotherapeutic agents Kaplan-Meier estimates of overall survival among the whole cohort (A) and among patients eligible for inclusion in a clinical trial (B). Back to article page